CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $71.75 Consensus Price Target from Brokerages

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) has been given an average rating of "Moderate Buy" by the seventeen brokerages that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and ten have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $71.75.

A number of research firms have issued reports on CRSP. JMP Securities restated a "market outperform" rating and set a $86.00 price target on shares of CRISPR Therapeutics in a report on Friday, June 27th. Piper Sandler reaffirmed an "overweight" rating and set a $105.00 target price on shares of CRISPR Therapeutics in a research report on Friday, June 27th. The Goldman Sachs Group lowered their price target on CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating for the company in a research report on Thursday, May 8th. Chardan Capital reaffirmed a "buy" rating and set a $82.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, June 26th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $81.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, July 8th.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ:CRSP traded up $10.04 during midday trading on Wednesday, hitting $65.13. 10,155,091 shares of the stock were exchanged, compared to its average volume of 1,994,222. The stock has a market capitalization of $5.62 billion, a price-to-earnings ratio of -14.41 and a beta of 1.82. The business's 50-day moving average price is $44.67 and its 200 day moving average price is $41.86. CRISPR Therapeutics has a 12 month low of $30.04 and a 12 month high of $66.10.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 20.08% and a negative net margin of 1,023.64%. CRISPR Therapeutics's revenue was up 71.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.43) EPS. As a group, sell-side analysts expect that CRISPR Therapeutics will post -5.16 EPS for the current year.

Insider Activity

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,932 shares of the firm's stock in a transaction dated Thursday, May 29th. The stock was sold at an average price of $35.94, for a total value of $141,316.08. Following the sale, the insider owned 6,068 shares of the company's stock, valued at $218,083.92. This trade represents a 39.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Simeon George purchased 989,812 shares of the stock in a transaction on Wednesday, July 16th. The stock was acquired at an average cost of $52.03 per share, for a total transaction of $51,499,918.36. Following the acquisition, the director owned 1,730,179 shares in the company, valued at approximately $90,021,213.37. This represents a 133.69% increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 4.30% of the company's stock.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of large investors have recently modified their holdings of CRSP. SVB Wealth LLC purchased a new position in shares of CRISPR Therapeutics during the 1st quarter valued at about $25,000. Costello Asset Management INC purchased a new position in shares of CRISPR Therapeutics during the 1st quarter valued at about $27,000. Wood Tarver Financial Group LLC purchased a new position in shares of CRISPR Therapeutics during the 4th quarter valued at about $30,000. Ameriflex Group Inc. purchased a new position in shares of CRISPR Therapeutics during the 4th quarter valued at about $36,000. Finally, Quantbot Technologies LP raised its holdings in shares of CRISPR Therapeutics by 272.4% during the 1st quarter. Quantbot Technologies LP now owns 1,337 shares of the company's stock valued at $45,000 after buying an additional 978 shares in the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.